Clinical Trial Update: Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK） [Phase 2]

View source ↗

Summary

Phase 2 SPARK trial evaluating total neoadjuvant therapy for pMMR/MSS locally advanced rectal cancer using short-course radiotherapy followed by sequential chem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PD-1 monoclonal antibody

Snippet

Sponsor: Dechang Diao | Conditions: pMMR/MSS Locally Advanced Rectal Cancer | Phase 2 | Status: RECRUITING